Park Hae-Young, Cheon Hyo-Bin, Choi Sun Ha, Kwon Jin-Won
BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, South Korea.
Lung Cancer Center, Kyungpook National University Chilgok Hospital, Daegu, South Korea.
Front Pharmacol. 2021 Apr 14;12:659675. doi: 10.3389/fphar.2021.659675. eCollection 2021.
Tuberculosis (TB) has significant effects on patients' health-related quality of life (HRQOL) and this study was conducted to evaluate the HRQOL based on EQ-5D utility score according to various health statuses of TB patients. A systematic literature review was conducted to select articles on HRQOLs outcomes of TB patients since 2000. A total of 1,710 articles were searched for primary screening and seven studies that directly assessed all types of TB patients using the EQ-5D were finally selected. The EQ-5D scores of TB patients were in the ranges of 0.43-0.70. After the completion of TB treatment, the utility weights increased to the ranges of 0.88-0.98 and the EQ VAS values showed similar trend as the results of the EQ-5D. The EQ-5D score for multi-drug-resistant TB was very low at 0.51 during treatment but increased to 0.88 after the treatment was completed. The utility weights of latent TB were not significantly different from those of the general population. This study showed that the HRQOL based on the EQ-5D utility score of TB patients has significantly decreased, and the TB treatment has a significantly positive effect on the quality of life of patients.
结核病（TB）对患者的健康相关生活质量（HRQOL）有重大影响，本研究旨在根据结核病患者的不同健康状况，基于EQ-5D效用评分评估其HRQOL。进行了一项系统的文献综述，以筛选自2000年以来关于结核病患者HRQOL结果的文章。共检索到1710篇文章进行初步筛选，最终选取了7项使用EQ-5D直接评估各类结核病患者的研究。结核病患者的EQ-5D评分在0.43 - 0.70范围内。完成结核病治疗后，效用权重增加到0.88 - 0.98范围内，EQ VAS值显示出与EQ-5D结果相似的趋势。耐多药结核病患者在治疗期间的EQ-5D评分很低，为0.51，但治疗完成后升至0.88。潜伏性结核病的效用权重与一般人群无显著差异。本研究表明，基于EQ-5D效用评分的结核病患者HRQOL显著下降，而结核病治疗对患者生活质量有显著的积极影响。
